Moderna, Inc. (MRNA) company profile
Close on Nov 17, 2026Market cap $82.56BP/E –Yield –
About Moderna
Biological Products, (No Diagnostic Substances), SIC 2836
Moderna is a biotechnology company focused on discovering, developing, and manufacturing medicines and vaccines powered by messenger RNA technology. Its commercial product lineup features respiratory immunizations, including Spikevax and mNEXSPIKE for COVID-19, as well as mRESVIA targeting respiratory syncytial virus. The firm organizes its pipeline across infectious diseases, oncology therapeutics, and rare disease treatments, actively evaluating candidates in late-stage clinical trials. Its products serve global populations spanning infants, high-risk individuals, and older adults, reaching patients through retail distribution, clinical healthcare settings, and government collaborations.
The enterprise operates a global manufacturing network with corporate and production facilities across the United States, the United Kingdom, Canada, and Australia, including a dedicated clinical batch supply center in Marlborough, Massachusetts. While corporate headquarters are not explicitly identified in the provided text, Moderna supplies and authorizes its medicines across more than forty international countries throughout North America, Europe, and the Asia-Pacific region.
Summary of the business section of Moderna's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Moderna, Inc.
- Founded
- 2010
- Headquarters
- Cambridge, MA
- Address
- 325 Binney Street 02142
- Phone
- (617) 714-6500
- Website
- www.modernatx.com
- Employees
- 4,700, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst & Young LLP, Boston, Massachusetts
Stock & identifiers
- Ticker
- MRNA
- Exchange
- Nasdaq
- IPO date
- Dec 7, 2018
- Shares outstanding
- 399M, Jul 24, 2026
- Public float
- $9.90B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1682852
- CUSIP
- 60770K107
- ISIN
- US60770K1079
- FIGI
- BBG003PHHZT1
- Share class FIGI
- BBG003PHHZV8
- LEI
- 549300EI6OKH5K5Q2G38
- EIN
- 81-3467528
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Stephane Bancel | Chief Executive Officer, Director | 13,005,140 |
| Juan Andres | Chief Operating Officer | 125,000 |
| Stephen Hoge | President | 1,792,614 |
| James M. Mock | Chief Financial Officer | 60,125 |
| Shannon Thyme Klinger | Chief Legal Officer | 87,044 |
| Soria Ester Banque | Chief Commercial Officer | – |
| Michael R. McDonnell | Director | – |
| Noubar Afeyan | Director | 6,856,164 |
| Abbas Hussain | Director | 12,066 |
| David M. Rubenstein | Director | 9,643 |
| Elizabeth E. Tallett | Director | 4,761 |
| Elizabeth G. Nabel | Director | 19,317 |
| Francois Nader | Director | 32,781 |
| Sandra Horning | Director | 18,585 |
| Paul Sagan | Director | 494,133 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $19.93M | $15.80M | $9.77M | $28 | $120 |
| FY2024 | $19.88M | $5.78M | $14.59M | $40 | $91 |
| FY2023 | $17.07M | -$155.55M | $5.10M | $95 | $92 |
| FY2022 | $19.36M | -$306.22M | $5.82M | $172 | $89 |
| FY2021 | $18.16M | $793.04M | $8.26M | $243 | $99 |
| FY2020 | $12.86M | $469.97M | $5.29M | $534 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| Stéphane Bancel Chief Executive Officer | $1.68M | $6.90M | $6.90M | $4.30M | $157.24K | $19.93M | +0% |
| James Mock Chief Financial Officer | $852.19K | $2.45M | $1.23M | $1.31M | $15.75K | $5.86M | -66% |
| Stephen Hoge President | $1.26M | $9.20M | $4.60M | $2.98M | $15.75K | $18.05M | +97% |
| Shannon Thyme Klinger Chief Legal Officer and Corporate Secretary | $852.19K | $2.15M | $1.07M | $1.31M | $15.75K | $5.40M | -69% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Dec 7, 2018
- Offer price
- $23.00
- Securities offered
- 26,275,993
- Gross proceeds
- $604.35M
- Exchange
- Nasdaq
- First trading day
- Dec 7, 2018
- First-day close
- $18.60-19.1%
- Lock-up ends (est.)
- Jun 5, 2019
“The initial public offering price of our common stock is $23.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“We had approximately 4,700 full-time employees in 18 countries as of December 31, 2025 .”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Dec 7, 2018 | IPO | Initial public offering priced (424B4 prospectus) |
| Dec 4, 2018 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 24, 2016 | Name change | Name changed from Moderna Therapeutics, Inc. to Moderna, Inc. |
See a number that looks wrong?